Europe Epilepsy Drugs Market Forecast to 2030

Europe Epilepsy Drugs Market Forecast to 2030

Europe Epilepsy Drugs Market Forecast to 2030 – Regional Analysis – by Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others)

Send Enquiry
Item ID: BMIRE00029809 Category: Tag:

$2,485 – $3,885

Description

The Europe epilepsy drugs market was valued at US$ 1,941.16 million in 2022 and is expected to reach US$ 2,626.05 million by 2030; it is estimated to grow at a CAGR of 3.8% from 2022 to 2030.

Increasing Number of Elderly People Fuels the Europe Epilepsy Drugs Market

Epilepsy is one of the prevalent neurological disorders affecting the geriatric population. According to the National Center for Biotechnology Information, epilepsy is the third most common neurological disorder affecting the elderly after dementia and stroke. The incidence of epilepsy is increasing in older adults, partly because of the growing prevalence of stroke, brain tumors, and dementia. Considering that modern society is aging, the overall prevalence and incidence of epilepsy are expected to rise.

The Eurostat statistics indicate that over one-fifth (21.1%) of the European population was aged 65 or more in 2022. According to an article published by UpToDate Inc. in August 2021, the incidence rate of epilepsy rises with age and is highest among patients aged 75 and above.

Therefore, due to the growing geriatric population, there is notable surge in conditions such as epilepsy owing to which the market for epilepsy drugs witnesses a significant growth.

Europe Epilepsy Drugs Market Overview

The Europe epilepsy drugs market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy drugs market. The European epilepsy drugs market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.

Europe Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

Europe Epilepsy Drugs Market Segmentation

The Europe epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Europe epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Europe epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Europe epilepsy drugs market is segmented Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, and UCB SA are some of the leading companies operating in the Europe epilepsy drugs market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

Year of Publication:

At 3.8% CAGR, the Europe Epilepsy Drugs Market is Speculated to be Worth US$ 2,626.05 million by 2030, Says the Research Team

According to the Research Team’ research, the Europe epilepsy drugs market was valued at US$ 1,941.16 million in 2022 and is expected to reach US$ 2,626.05 million by 2030, registering a CAGR of 3.8% from 2022 to 2030. Several epilepsy drugs nearing patent expiration and increasing product approvals are among the critical factor attributed to the Europe epilepsy drugs market expansion.

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

On the contrary, recall of therapeutic products hampers the growth Europe epilepsy drugs market.

Based on treatment, the Europe epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held 42.7% share of the Europe epilepsy drugs market in 2022, amassing US$ 829.38 million. It is projected to garner US$ 1,161.56 million by 2030 to expand at 4.3% CAGR during 2022-2030.

Based distribution channel, the Europe epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held 51.2% share of the Europe epilepsy drugs market in 2022, amassing US$ 994.70 million. It is projected to garner US$ 1,302.06 million by 2030 to expand at 3.4% CAGR during 2022-2030.

Based on country, the Europe epilepsy drugs market is categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK held 23.8% share of Europe epilepsy drugs market in 2022, amassing US$ 461.70 million. It is projected to garner US$ 664.36 million by 2030 to expand at 4.7% CAGR during 2022-2030.

Key players operating in the Europe epilepsy drugs market are Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, and UCB SA, among others.

In September 2023; Sanofi sold Pharmanovia, a firm established in the United Kingdom, 11 brands from its portfolio related to the central nervous system, including the epilepsy medications Gardenal and Frisium. Eleven brands from Sanofi’s portfolio related to the central nervous system, including the epilepsy medications Frisium and Gardenal, were transferred to Pharmanovia, a firm based in the UK. Along with Tercian, which treats anxiety and psychotic problems in patients who have already failed other medications, Sanofi is also getting rid of the epilepsy medication Gardenal and the nausea and vertigo medication Stemetil.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe epilepsy drugs market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in Europe epilepsy drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution

TABLE OF CONTENTS

1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Epilepsy Drugs Landscape
4.1 Overview
5. Europe Epilepsy Drugs Market – Key Industry Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Epilepsy
5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
5.4.1 Increasing Product Approvals
5.5 Impact Analysis
6. Epilepsy Drugs Market – Europe Market Analysis
6.1 Overview
6.2 Europe Epilepsy Drugs Market Revenue (US$ Mn), 2022 – 2030
7. Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Treatment
7.1 Overview
7.2 Europe Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
7.3.1 Overview
7.3.2 First Generation Antiepileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
7.4.1 Overview
7.4.2 Second Generation Anti-epileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
7.5.1 Overview
7.5.2 Third Generation Anti-epileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 – by Distribution Channel
8.1 Overview
8.2 Europe Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
8.3.1 Overview
8.3.2 Hospital Pharmacy: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
8.4.1 Overview
8.4.2 Retail Pharmacy Stores: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 – Country Analysis
9.1 Europe Epilepsy Drugs Market, by Key Country – Revenue (2022) (US$ Million)
9.1.1 Europe Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
9.1.1.1 Germany: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.1 Overview
9.1.1.1.2 Germany: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.1.3 Germany: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.1.4 Germany: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.2 France: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 France: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.3 France: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.2.4 France: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.3 UK: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 UK: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.3 UK: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.3.4 UK: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.4 Italy: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Overview
9.1.1.4.2 Italy: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.3 Italy: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.4.4 Italy: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.5 Spain: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.5.1 Overview
9.1.1.5.2 Spain: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.5.3 Spain: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.5.4 Spain: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.1.6 Rest of Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.6.1 Overview
9.1.1.6.2 Rest of Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.6.3 Rest of Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
9.1.1.6.4 Rest of Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Epilepsy Drugs Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
10.3.1 Overview
10.4 Organic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 UCB SA
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Novartis AG
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Pfizer Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 GSK Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Abbott Laboratories
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Sanofi SA
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Teva Pharmaceutical Industries Ltd
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Alkem Laboratories Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

LIST OF TABLES

Table 1. Epilepsy Drugs Segmentation
Table 2. Germany: Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 3. Germany: Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 4. France: Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 5. France: Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 6. UK: Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 7. UK: Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 8. Italy: Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 9. Italy: Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 10. Spain: Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 11. Spain: Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 12. Rest of Europe Epilepsy Drugs Market, by Treatment – Revenue and Forecast to 2030 (US$ Million)
Table 13. Rest of Europe Epilepsy Drugs Market, by Distribution Channel – Revenue and Forecast to 2030 (US$ Million)
Table 14. Recent Inorganic Growth Strategies in the Europe Epilepsy Drugs Market
Table 15. Recent Organic Growth Strategies in the Europe Epilepsy Drugs Market
Table 16. Glossary of Terms, Europe Epilepsy Drugs Market

LIST OF FIGURES

Figure 1. Epilepsy Drugs Segmentation, By Country
Figure 2. Europe Epilepsy Drugs Market: Key Industry Dynamics
Figure 3. Europe Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
Figure 4. Europe Epilepsy Drugs Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Europe Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 6. First Generation Anti-epileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Second Generation Anti-epileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Third Generation Anti-epileptics: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 10. Hospital Pharmacy: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Retail Pharmacy Stores: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Others: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Europe Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 14. Germany: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. France: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. UK: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Italy: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. Spain: Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Rest of Europe Epilepsy Drugs Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Growth Strategies in the Epilepsy Drugs Market

The List of Companies – Europe Epilepsy Drugs Market

1. Abbott Laboratories
2. Alkem Laboratories Ltd
3. GSK Plc
4. Novartis AG
5. Pfizer Inc
6. Sanofi SA
7. Teva Pharmaceutical Industries Ltd
8. UCB SA

Reviews

There are no reviews yet.

Be the first to review “Europe Epilepsy Drugs Market Forecast to 2030”